Manthena V S Varma

List of Publications by Year in Descending Order

46 papers	1,708 citations	25 h-index	41 g-index
48 ext. papers	2,007 ext. citations	5.1 avg, IF	4.86 L-index

#	Paper	IF	Citations
46	Drug-Drug Interactions Involving Renal OCT2/MATE Transporters: Clinical Risk Assessment May Require Endogenous Biomarker-Informed Approach. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 855-859	6.1	4
45	Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling. *CPT: Pharmacometrics and Systems Pharmacology*, **2021**, 10, 1018-1031	4.5	2
44	Effect of Human Plasma on Hepatic Uptake of Organic Anion-Transporting Polypeptide 1B Substrates: Studies Using Transfected Cells and Primary Human Hepatocytes. *Drug Metabolism and Disposition*, **2021**, 49, 72-83	4	6
43	Organic Anion-Transporting Polypeptide 1B1/1B3-Mediated Hepatic Uptake Determines the Pharmacokinetics of Large Lipophilic Acids: In Vitro-In Vivo Evaluation in Cynomolgus Monkey. *Journal of Pharmacology and Experimental Therapeutics*, **2021**, 377, 169-180	4.7	2
42	Cytochrome-P450-Mediated DrugDrug Interactions of Substrate Drugs: Assessing Clinical Risk Based on Molecular Properties and an Extended Clearance Classification System. *Molecular Pharmaceutics*, **2020**, 17, 3024-3032	5.6	5
41	Nicotinic acid transport into human liver involves organic anion transporter 2 (SLC22A7). *Biochemical Pharmacology*, **2020**, 174, 113829	6	9
40	Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?. *Drug Metabolism and Disposition*, **2020**, 48, 205-216	4	16
39	Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs. *Journal of Medicinal Chemistry*, **2020**, 63, 11831-11844	8.3	5
38	Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting. *Journal of Medicinal Chemistry*, **2020**, 63, 10879-10896	8.3	5
37	In Vivo-to-In Vitro Extrapolation of Transporter-Mediated Renal Clearance: Relative Expression Factor Versus Relative Activity Factor Approach. *Drug Metabolism and Disposition*, **2020**, 49, 470-478	4	4
36	Quantitative Proteomics and Mechanistic Modeling of Transporter-Mediated Disposition in Nonalcoholic Fatty Liver Disease. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 1128-1137	6.1	21
35	Transporter-enzyme interplay and the hepatic drug clearance: what have we learned so far?. *Expert Opinion on Drug Metabolism and Toxicology*, **2020**, 16, 387-401	5.5	7
34	Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. *Drug Metabolism and Disposition*, **2019**, 47, 493-503	4	12
33	Quantitative Contribution of Six Major Transporters to the Hepatic Uptake of Drugs: "SLC-Phenotyping" Using Primary Human Hepatocytes. *Journal of Pharmacology and Experimental Therapeutics*, **2019**, 370, 72-83	4.7	36
32	Clopidogrel as a Perpetrator of Drug-Drug Interactions: A Challenge for Quantitative Predictions?. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 1295-1299	6.1	5
31	Effect of Hepatic Organic Anion-Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver-Targeted Glucokinase Activator: A Model-Based Evaluation. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 792-802	6.1	10
30	Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation. *Molecular Pharmaceutics*, **2018**, 15, 1284-1295	5.6	29

29	Navigating Transporter Sciences in Pharmacokinetics Characterization Using the Extended Clearance Classification System. *Drug Metabolism and Disposition*, **2018**, 46, 729-739	4	31
28	Comparison of Proteomic Quantification Approaches for Hepatic Drug Transporters: Multiplexed Global Quantitation Correlates with Targeted Proteomic Quantitation. *Drug Metabolism and Disposition*, **2018**, 46, 692-696	4	22
27	Organic Anion Transporter 2 Mediates Hepatic Uptake of Tolbutamide, a CYP2C9 Probe Drug. *Journal of Pharmacology and Experimental Therapeutics*, **2018**, 364, 390-398	4.7	29
26	Quantification of Hepatic Organic Anion Transport Proteins OAT2 and OAT7 in Human Liver Tissue and Primary Hepatocytes. *Molecular Pharmaceutics*, **2018**, 15, 3227-3235	5.6	16
25	Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey. *Drug Metabolism and Disposition*, **2018**, 46, 1179-1189	4	25
24	Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. *Journal of Pharmacology and Experimental Therapeutics*, **2018**, 367, 322-334	4.7	30
23	Reliable Rate Measurements for Active and Passive Hepatic Uptake Using Plated Human Hepatocytes. *AAPS Journal*, **2017**, 19, 787-796	3.7	32
22	Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach. *Drug Metabolism and Disposition*, **2017**, 45, 409-417	4	61
21	Transporter-Mediated Disposition, Clinical Pharmacokinetics and Cholestatic Potential of Glyburide and Its Primary Active Metabolites. *Drug Metabolism and Disposition*, **2017**, 45, 737-747	4	6
20	Hepatobiliary Clearance Prediction: Species Scaling From Monkey, Dog, and Rat, and In‐Vitro‐In‐Vivo Extrapolation of Sandwich-Cultured Human Hepatocytes Using 17 Drugs. *Journal of Pharmaceutical Sciences*, **2017**, 106, 2795-2804	3.9	43
19	Molecular properties associated with transporter-mediated drug disposition. *Advanced Drug Delivery Reviews*, **2017**, 116, 92-99	18.5	13
18	Extended Clearance Classification System (ECCS) informed approach for evaluating investigational drugs as substrates of drug transporters. *Clinical Pharmacology and Therapeutics*, **2017**, 102, 33-36	6.1	27
17	Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast. *Clinical Pharmacology and Therapeutics*, **2017**, 101, 406-415	6.1	36
16	Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?. *CPT: Pharmacometrics and Systems Pharmacology*, **2016**, 5, 505-515	4.5	13
15	Dealing with the complex drug-drug interactions: towards mechanistic models. *Biopharmaceutics and Drug Disposition*, **2015**, 36, 71-92	1.7	48
14	Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide. *Drug Metabolism and Disposition*, **2015**, 43, 1108-18	4	54
13	Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved. *Clinical Pharmacokinetics*, **2014**, 53, 659-78	6.2	81
12	Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. *AAPS Journal*, **2014**, 16, 736-48	3.7	39

11	Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1B1 substrates using a mechanistic net-effect model. *Journal of Pharmacology and Experimental Therapeutics*, **2014**, 351, 214-23	4.7	54
10	Response to the comment on the article "physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions". *Pharmaceutical Research*, **2013**, 30, 1469-70	4.5	3
9	Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. *Pharmaceutical Research*, **2013**, 30, 1188-99	4.5	86
8	Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. *Expert Opinion on Drug Metabolism and Toxicology*, **2013**, 9, 459-72	5.5	55
7	Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. *Drug Metabolism and Disposition*, **2013**, 41, 966-74	4	52
6	Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. *Pharmaceutical Research*, **2012**, 29, 2860-73	4.5	109
5	Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion. *Drug Metabolism and Disposition*, **2012**, 40, 1527-37	4	58
4	pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. *Molecular Pharmaceutics*, **2011**, 8, 1303-13	5.6	83
3	Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state. *Expert Opinion on Drug Metabolism and Toxicology*, **2010**, 6, 939-52	5.5	73
2	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. *Journal of Medicinal Chemistry*, **2010**, 53, 1098-108	8.3	197
1	Physicochemical determinants of human renal clearance. *Journal of Medicinal Chemistry*, **2009**, 52, 4844-52	5.5	153